Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a
standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The
study is also intended to collect first data on the effects of the combination of BMS-754807
with cetuximab on tumors of patients with colorectal cancer or squamous cell cancer of the
head and neck for whom cetuximab-containing therapies have not been effective